API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
BGB 324 (bemcentinib) is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase (AXL). It is being evaluated for the treatment of STK11 mutated Non-Small Lung Cancer.
Lead Product(s): Bemcentinib,Pembrolizumab,Pemetrexed
Therapeutic Area: Oncology Product Name: BGB 324
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
BGB324 (bemcentinib) is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase (AXL). It is being evaluated in preclinical trials for the treatment of infection caused by Respiratory Syncytial Virus.
Lead Product(s): Bemcentinib
Therapeutic Area: Infections and Infectious Diseases Product Name: BGB324
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Details:
BGB324 (bemcentinib) is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase (AXL) a promising therapeutic target for serious diseases. It is being developed for the treament of NSCLC.
Lead Product(s): Bemcentinib,Pembrolizumab,Pemetrexed
Therapeutic Area: Oncology Product Name: BGB324
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
BGB324 (bemcentinib) is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase (AXL) a promising therapeutic target for serious diseases. It is being investigated for non-small cell lung cancer (NSCLC).
Lead Product(s): Bemcentinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: BGB324
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
The facility will enable BerGenBio to continue its previously announced focused strategy of advancing its lead compound bemcentinib (BGB324) in 1st line Non-Small Cell Lung Cancer (NSCLC) and hospitalized COVID-19 patients.
Lead Product(s): Bemcentinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: BGB324
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Meteva AS
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing October 25, 2022
Details:
Complete data analysis confirms that the primary endpoint of improved clinical response and key secondary endpoints were met in a subprotocol under the platform ACCORD2 study where bemcentinib was added to standard of care therapy.
Lead Product(s): Bemcentinib
Therapeutic Area: Infections and Infectious Diseases Product Name: BGB324
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
Pre-clinical NSCLC mouse models harboring STK11 mutations, sensitivity to PD-1 blockade was evaluated in the absence and presence of bemcentinib. Systemic inhibition of AXL with bemcentinib resulted in expansion of tumor-associated T cells and restored therapeutic response.
Lead Product(s): Bemcentinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: BGB324
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
In total, 179 eligible patients were enrolled across both studies between May 2020 and March 2021, randomly allocated on an open-label basis to treatment with bemcentinib in addition to standard of care (SoC) compared to SoC alone.
Lead Product(s): Bemcentinib
Therapeutic Area: Infections and Infectious Diseases Product Name: BGB324
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University Hospital Southampton
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2021
Details:
The data indicate that the combination of bemcentinib, a once-daily oral AXL-inhibitor and LDAC is efficacious and well tolerated in the elderly and unfit relapsed AML population.
Lead Product(s): Bemcentinib,Cytarabine
Therapeutic Area: Oncology Product Name: BGBC003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
Ongoing clinical trials are investigating bemcentinib in COVID-19, and multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single agent.
Lead Product(s): Bemcentinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: BGB324
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2021
Details:
The data indicates that treatment with the bemcentinib-LDAC combination shows promising efficacy in relapsed patients who are unfit for intensive chemotherapy.
Lead Product(s): Bemcentinib,Cytarabine
Therapeutic Area: Oncology Product Name: BGB 324
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2020
Details:
The combination of bemcentinib and pembrolizumab was overall shown to be well tolerated and clinically active in CPI-refractory composite AXL (cAXL) positive NSCLC.
Lead Product(s): Bemcentinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: BGB324
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
This is an open label, multi-centre, intra-tumoral tissue pharmacokinetic (PK) study of bemcentinib in patients with recurrent glioblastoma for whom a surgical resection is medically indicated.
Lead Product(s): Bemcentinib
Therapeutic Area: Oncology Product Name: BGB 324
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Alabama
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
The presentation to be given will provide an update of results from a phase II trial, evaluating bemcentinib in combination with MSD’s Keytruda in previously treated non-small cell lung cancer (NSCLC) patients.
Lead Product(s): Bemcentinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
Details:
Dosing has commenced in the UK Government-backed Phase II clinical trial assessing bemcentinib in hospitalised COVID-19 patients. Bemcentinib was selected as the first candidate to be tested as part of the ACcelerating COVID-19 Research & Development platform (ACCORD) study.
Lead Product(s): Bemcentinib
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
Preclinical data suggest that bemcentinib is potentially useful for the treatment of early SARS-CoV-2 infection. There are currently no approved medical treatments for, or vaccines against, COVID-19.
Lead Product(s): Bemcentinib
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2020
Details:
The clinical efficacy endpoint met for the Phase II trial cohort evaluating selective AXL inhibitor bemcentini- Keytruda combo, in patients with advanced NSCLC who failed checkpoint inhibitor therapy.
Lead Product(s): Bemcentinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2020